RAD.ASX: RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

RAD advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

Stock	Radiopharm Theranostics Ltd (RAD.ASX)
Release Time	20 Aug 2026, 8:51 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

RAD Advances to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Trial

Key Points

Positive recommendation from DSMC to advance to Cohort 4
Next dose level of 180mCi for patients with HER2+ solid tumors
Previous study showed positive safety and biodistribution

Full Summary

Radiopharm Theranostics has received a positive recommendation from the Data Safety and Monitoring Committee (DSMC) to advance its clinical-stage radiotherapeutic asset, 177Lu-RAD202 (RAD202), to the next dose level of 180mCi in the Phase 1 'HEAT' clinical trial. The trial is focused on patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors. This advancement follows a previous diagnostic study of RAD202 in ten HER2-positive breast cancer patients, which demonstrated clinical proof-of-concept with positive safety and biodistribution.

Outlook

The DSMC's recommendation supports the favorable safety profile observed to date and allows us to continue evaluating higher dose levels in patients with HER2-positive advanced solid tumors.